Author

William Sandborn 1

1 University of California San Diego,La Jolla,United States

CORTICOSTEROID DOSE REDUCTION WITH VEDOLIZUMAB TREATMENT OF CROHN’S DISEASE

Edward V. Loftus Jr., Corey A Siegel, Remo Panaccione, William Sandborn, Michael Smyth, Alexandra Green, Jing Xu, Brihad Abhyankar

Corticosteroid Sparing Effects of Ustekinumab Therapy in Ulcerative Colitis Patients: Results From the UNIFI Program

Silvio Danese, Bruce E. Sands, Laurent Peyrin-Biroulet, C Marano, Christopher O’Brien, Hongyan Zhang, Alessandra Nunes Faria Oortwijn, David Rowbotham, Rupert W Leong, Ramesh P. Arasaradnam, Gert Van Assche, William Sandborn, Remo Panaccione

CORTICOSTEROID-FREE REMISSION OF ULCERATIVE COLITIS WITH FILGOTINIB MAINTENANCE THERAPY: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY

Edward V Loftus Jr, Severine Vermeire, Brian Feagan, Chohee Yun, Jeremy Hsieh, Xiaopeng Liu, Sally Zhao, Ulrik Moerch, William J. Sandborn, Toshifumi Hibi

CORTICOSTEROID-SPARING EFFECTS OF USTEKINUMAB THERAPY FOR ULCERATIVE COLITIS THROUGH 4 YEARS: UNIFI LONG-TERM EXTENSION

Ramesh P. Arasaradnam, Ellen J. Scherl, David Rowbotham, Silvio Danese, William J. Sandborn, Ye Miao, Hongyan Zhang, Remo Panaccione, Waqqas Afif, Tadakazu Hisamatsu, Rupert W Leong, Bruce E. Sands, Maria T. Abreu, Colleen W. Marano

DE-ESCALATING THERAPY IN PATIENTS WITH CROHN'S DISEASE RECEIVING ADALIMUMAB: A SUBGROUP ANALYSIS OF THE CALM STUDY

Peter Bossuyt, Geert R. D'Haens, Remo Panaccione, William Sandborn, Walter Reinisch, Simon Travis, Stefan Schreiber, Alessandro Armuzzi, Silvio Danese, Sofie Berg, Joel Petersson, Jen-Fue Maa, Ezequiel Neimark, Jean-Frederic Colombel

DIFFERENT METHODOLOGIES FOR DETERMINING MAYO SCORE IN CLINICAL STUDIES CAN INFLUENCE DISEASE ACTIVITY ASSESSMENTS IN ULCERATIVE COLITIS

Subrata Ghosh, William Sandborn, Julian Panés, Geert R. D'Haens, Nattanan Reilly, Andreas Lazar, Bidan Huang, Anne M. Robinson, Roopal B Thakkar

DURABILITY OF CLINICAL REMISSION WITH VEDOLIZUMAB IN CROHN’S DISEASE

William Sandborn, Silvio Danese, Brihad Abhyankar, Walter Reinisch, Catherine Milch

EARLY AND DURABLE SYMPTOM CONTROL IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH ETRASIMOD (APD334) IN THE RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 OASIS TRIAL AND OPEN LABEL EXTENSION

Michael Chiorean, Severine Vermeire, Julian Panés, Laurent Peyrin-Biroulet, Jinkun Zhang, Bruce E. Sands, Chris Cabell, Snehal U. Naik, William Sandborn

EARLY AND SUSTAINED REMISSION AFTER TREATMENT WITH SC ADMINISTERED GOLIMUMAB IS ASSOCIATED WITH NORMALIZED HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: POSTHOC-ANALYSIS FROM PURSUIT INDUCTION AND MAIN

Walter Reinisch, Brian G. Feagan, Colleen W. Marano, Richard S Strauss, C. Han, T Gathany, Jewel Johanns, Hongjie Zhang, Peter R. Gibson, John Collins, Paul Rutgeerts, Jean-Frederic Colombel, Brian G. Feagan, Gunnar Jarnerot, William Sandborn

EARLY PRO-2 SYMPTOM REMISSION FOLLOWING GUSELKUMAB INDUCTION TREATMENT: RESULTS THROUGH WEEK 12 OF THE PHASE 2 GALAXI 1 STUDY

William J. Sandborn, Tadakazu Hisamatsu, Kathleen Weisel, Susana Gonzalez, Mary Ellen Frustaci, Zijiang Yang, Jewel Johanns, Matthew Germinaro, Brian Feagan, Aniita Afzali, Walter Reinisch, Jane Andrews, Omoniyi J. Adedokun, Chenglong Han

Item 31 - 40 / 206
1 2 3
4
5 6 7
...
20 21